Morning Glory Sciences– Author –
After completing graduate school, I studied at a Top tier research hospital in the U.S., where I was involved in the creation of treatments and therapeutics in earnest. I have worked for several major pharmaceutical companies, focusing on research, business, venture creation, and investment in the U.S. During this time, I also serve as a faculty member of graduate program at the university.
-
FDA Treatment News: FDA Eliminates REMS for Autologous CAR-T Cell Therapies
[Regulatory Update] FDA Removes REMS Requirements for Approved CAR-T Therapies In June 2025, the U.S. Food and Drug Administration (FDA) officially eliminated Risk Evaluation and Mitigation Strategies (REMS) requirements for autologous c... -
Biotech Investment News: Vertex’s Major Biotech Deals (2015–2025)
Strategic Review: From Cystic Fibrosis to Gene Editing and Regenerative Medicine Vertex Pharmaceuticals has leveraged its dominance in cystic fibrosis (CF) treatment to expand into gene editing, regenerative medicine, pain management, an... -
Biotech Investment News: Regeneron’s Major Biotech Deals (2015–2025)
Strategic Review: Antibody Innovation Meets Gene Editing and RNA Technology Regeneron Pharmaceuticals has leveraged its VelociSuite antibody platform to become a leader in ophthalmology, oncology, and immunology. Over the last decade, it... -
Biotech Investment News: Novo Nordisk’s Major Deals from 2015 to 2025
Strategic Overview: Expanding from Diabetes to Obesity, RNA, and Cardiometabolic Disease Novo Nordisk, known for its leadership in GLP-1 receptor agonists (Ozempic, Wegovy), has expanded significantly over the past decade. Through acquis... -
Biotech Investment News: Major Gilead Deals Over the Past Decade (2015–2025)
Strategic Review: Shifting from Antivirals to Oncology and Cell Therapy Gilead Sciences, once dominant in the antiviral space—particularly in HIV and hepatitis C—has been facing declining revenue due to patent cliffs. Since 2015, the com... -
Biotech Investment News: Bayer’s Major Biotech Deals (2015–2025)
Strategic Review: Building a Cell and Gene Therapy Pipeline with BlueRock and AskBio Over the past decade, Bayer has transitioned from conventional pharmaceuticals into emerging modalities like gene editing, cell therapies, and regenerat... -
Biotech Investment News: Major Pharmaceutical Deals of Boehringer Ingelheim (2015–2025)
Strategic Review: Diversifying into Oncology and Immunology Through Innovative Partnerships Boehringer Ingelheim (BI), traditionally strong in cardiovascular and respiratory areas, has pivoted towards oncology and immune diseases over th... -
Rare & Pediatric Disease News Vol.3: Are Adult Cancer Drugs Really Enough for Children?
Why Pediatric Oncology Requires Tailored Innovation From infancy to adulthood, the human body undergoes approximately two decades of dynamic growth. A newborn weighing 3,000 grams grows tenfold or more. Throughout this period, the endocr... -
[Science News] Cancer Discovery Spotlight: CAFs Suppress NK Cells to Promote Breast Cancer Metastasis
A study published in the June 2025 issue of Cancer Discovery reveals how cancer-associated fibroblasts (CAFs) promote metastatic progression in breast cancer by suppressing natural killer (NK) cell cytotoxicity. This work was selected fo... -
Biotech Investment News: Amgen’s Key Deals from 2015 to 2025
Strategic Review: From Biologics to Rare Diseases, Oncology, and RNA Innovation Over the past decade, Amgen has expanded beyond its legacy focus on bone and inflammatory diseases to invest heavily in oncology, RNA therapies, and rare dis... -
Biotech Investment News: Novartis’s Key Deals from 2015 to 2025
Strategic Review: From Blockbusters to Nuclear Medicine, Gene and Cell Therapy Over the past decade, Novartis has strategically shifted its focus toward high-value therapies, including nuclear medicine (Pluvicto), gene therapy (Zolgensma... -
【Biotech Investment News】Sanofi’s Strategic Deals in 2025: A Comprehensive Summary
Key Pharma Moves: Sanofi’s Acquisitions and Collaborations in Q1–Q3 2025 In 2025, Sanofi has executed several key strategic acquisitions and licensing deals focused on immunology, neurology, and rare diseases. Here's a summary of these d... -
Biotech Investment News: Eli Lilly’s Key Deals from 2015 to 2025
Strategic Overview: Dominance in Diabetes and Obesity with Oncology Expansion Eli Lilly has strengthened its global leadership in diabetes and obesity while expanding into oncology, neuroscience, and gene therapy. With the blockbuster su... -
Biotech Investment News: GSK’s Major Deals from 2015 to 2025
Strategic Review: Focused Expansion in Vaccines and Specialty Medicines Over the past decade, GSK has shifted from large-scale M&A to focused investments and strategic partnerships, particularly in vaccines, oncology, respiratory, an... -
Biotech Investment News: AstraZeneca’s 10-Year Deal Overview & 2025 Update (2015–2025)
Strategic Review: Investing in ADCs, Rare Diseases, and Biomanufacturing Capabilities AstraZeneca has expanded significantly in oncology through antibody and ADC partnerships, including a high-profile collaboration with Japan’s Daiichi S... -
[Science News] KRAS Inhibition and T-cell Dependency: Defining the Immune Role in Pancreatic Cancer Therapy (Cancer Discovery Summary / With My Thoughts)
A study published online in June 2025 in Cancer Discovery reveals that **T-cell–dependent tumor regression** is a key mechanism underlying the efficacy of KRAS G12D inhibitors in pancreatic ductal adenocarcinoma (PDAC). KRAS G12D is a ma... -
[Aging & Rejuvenation Science Series #2] GLP-1R Agonists May Mitigate Alzheimer’s via Energy Regulation: Insights from Nature Aging
In a May 2025 Nature Aging publication, Zhang and colleagues report that GLP-1 receptor agonists (GLP-1R agonists), widely used in the treatment of type 2 diabetes, may also alleviate Alzheimer’s disease (AD) symptoms in mice. Key Findin... -
Biotech Investment News: AbbVie’s Major Deals from 2015 to 2025
Strategic Review: Diversifying Beyond Humira AbbVie has proactively diversified its portfolio beyond Humira, expanding into oncology, neuroscience, immunology, ophthalmology, and aesthetics. Its acquisition of Allergan, ADC platforms, an... -
Biotech Investment News: Bristol Myers Squibb’s Major Deals (2015–2025)
Strategic Review: From Opdivo to Next-Gen Modalities BMS is known as a pioneer in immuno-oncology, with the development of Opdivo (nivolumab) and Yervoy (ipilimumab). Over the past decade, the company has expanded aggressively into new m... -
Biotech Investment News: Roche’s Major Deals Over the Past Decade (2015–2025)
Strategic Review: Expanding from Monoclonal Antibodies into Diagnostics, RNA, and Cell Therapy Roche has long been a global leader in monoclonal antibody-based cancer therapies. Over the past decade, the company has strategically expande...